Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation…
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist…
Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial A
June 05, 2026 19:30 ET | Source: Oban BioPharma, Inc. STAMFORD, Conn.,…
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and…
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
June 05, 2026 20:13 ET | Source: Bluejay Diagnostics, Inc. $8.5 million…
Data at ADA 2026 Highlights Key Findings from Clinical and RealWorld Studies of MannKinds Afrezza (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
Builds on recent FDA approval (May 29, 2026) of Afrezza for use…
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
Publication presented concurrently with oral presentation at American Diabetes Association’s 86th Scientific…
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
June 05, 2026 16:05 ET | Source: Shattuck Labs, Inc. AUSTIN, Texas…
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares
June 05, 2026 16:01 ET | Source: Jade Biosciences SAN FRANCISCO and…
